Hua Baojin and Lyu Wenliang, vice presidents of Guang'anmen Hospital, were selected as Qihuang Scholars
Time：2022-02-07
Recently, the National Administration of Traditional Chinese Medicine(TCM) announced the list of candidates for the Qihuang Scholars Support Project in 2021. Hua Baojin and Lyu Wenliang, vice presidents of our hospital, were successfully selected. There are 7 Qihuang Scholars in our hospital now.
Hua Baojin
Vice President and medical professor of Guang'anmen Hospital, MD, Postdoctor,
Chief researcher of the China Academy of Chinese Medical Sciences; Doctoral tutor;
Expert who have obtained special government allowances from the State Council;
Executive Deputy Director, Institute of Oncology, China Academy of Chinese Medical Sciences;
Director of the innovation team in key areas of the Ministry of Science and Technology;
The winner of the "Ten Thousand Talents Program" for leading scientific and technological innovation;
Young and middle-aged expert with outstanding contributions to national health and family planning;
The outstanding talent of first batch in TCM clinical practice by the National Administration of TCM;
Leader of key disciplines and key specialties of TCM oncology of the National Administration of TCM;
Secretary of the Party branch and honorary chairman of the Cancer Branch of the China Association of Chinese Medicine;
Member of the 10th and 11th National Pharmacopoeia Committee;
Chairman of China TCM Cancer Prevention and Control Alliance;
Member of China Association of Chinese Medicine.
He studied under Professor Duan Fujin, a national TCM master, and Professor Piao Bingkui, a famous TCM doctor in China. He inherited the idea of "strengthening body resistance and cultivating the foundation" in the treatment of tumors. He has been working in clinic for more than 30 years, and has accumulated rich clinical experience.
With preventive treatment idea, he is good at preventing and treating postoperative recurrence and metastasis of tumors, lung cancer, digestive system tumors, cancer-related symptoms and precancerous lesions with the methods of clearing and reducing turbidity, and activating qi and blood.
He founded the theory of "regulating qi and detoxifying" and applied it to the prevention and treatment of tumors in TCM, and developed a series of Shuangshen tumor prevention and treatment preparations. As the principal investigator of the national key research and development plan, from the "Tenth Five-Year Plan" to the "Thirteenth Five-Year Plan" period, he put forward the concept of tumor prevention and control：prevention first, combining prevention and treatment, and focusing on prevention； and established the first cancer prevention clinic in China. He focused his oncology clinical work on the prevention and rehabilitation of precancerous lesions, recurrence and metastasis, and gave full play to the characteristics and advantages of TCM "preventive treatment".
Lyu Wenliang
Vice President and medical professor of Guang'anmen Hospital;
Doctor of TCM in Digestion;
Postdoctor in oncology with integrated TCM and Western medicine;
Doctoral supervisor; postdoctoral cooperative supervisor;
Director of the sub-center of the liver disease clinical research base of the Ministry of Science and Technology;
Director and academic leader of "Twelfth Five-Year" key specialist in liver disease of National Administration of TCM;
Leader of Guang'anmen Hospital of the National TCM Medical Team to fight against COVID-19 in Wuhan, China;
Expert who have obtained special government allowances from the State Council;
Young and middle-aged TCM doctor of the first batch of China Academy of Chinese Medical Sciences;
Famous young and middle-aged TCM doctor in the capital;
Vice President and Secretary General of Chinese Association of Integrative Medicine;
Executive Director of Chinese Medical Association;
Member of the Expert Advisory Committee on Drug Safety and Risk Management and the Drug Registration Review Expert Advisory Committee of the State Food and Drug Administration;
The chief scientist of the project "Clinical Research of Yinqi Sanhuang Jiedu Decoction in the Treatment of Chronic Type B Viral Liver Disease" of " TCM Modernization Research of National Key Research and Development Program " of the Ministry of Science and Technology.
Under the Professor Yao Naili and Professor Sun Guizhi, famous TCM masters in the capital, he studied the comprehensive prevention and treatment of chronic stomach disease, chronic liver disease and liver cancer with TCM and Western medicine. He has a unique understanding of the etiology and pathogenesis of chronic hepatitis, liver cirrhosis and liver cancer by summarizing the experience of doctors in the past dynasties in treating chronic liver disease and combining with his own clinical practice.
He used the methods of invigorating qi and strengthening spleen, soothing liver and relieving depression, clearing dampness and heat, detoxifying, promoting circulation of collaterals and removing stasis to treat liver diseases. In accordance with the law of the development of TCM, he created Yinqi Sanhuang Jiedu Decoction, an experience prescription for preventing and treating chronic hepatitis, liver fibrosis, cirrhosis and liver cancer.
The decoction formula was formed under the guidance of the holism concept of TCM and the theories of treatment based on syndrome differentiation and preventive health care, and its scientific research had been supported by the Key Research Program for the TCM Modernization of National Key Research and Development Program.
As the chief scientist of the program and the leader of the sub-center of the liver disease clinical research base of the Ministry of Science and Technology, he also undertakes the research on major special projects of infectious diseases in the national 11th, 12th, and 13th Five-Year Plan.
He first proposed and advocated the Huo Hou theory of TCM . He is good at preventing and treating liver diseases with integrated TCM and Western medicine, and has unique curative effects on chronic atrophic gastritis and infertility.
He was the first to use clinical epidemiological methods to study the syndromes of hepatitis B fibrosis, filling the gap in the field of TCM research. In cooperation with the National Center for Nanomedicine, he carried out researches on the mechanisms of biomechanopharmacology, genomics after TCM intervention for chronic liver diseases, which are in a pioneering and leading position in China.
Vice President Lyu Wenliang treated patients at Dongxihu Fangcang Hospital in Wuhan, China
Hua Baojin
Vice President and medical professor of Guang'anmen Hospital, MD, Postdoctor,
Chief researcher of the China Academy of Chinese Medical Sciences; Doctoral tutor;
Expert who have obtained special government allowances from the State Council;
Executive Deputy Director, Institute of Oncology, China Academy of Chinese Medical Sciences;
Director of the innovation team in key areas of the Ministry of Science and Technology;
The winner of the "Ten Thousand Talents Program" for leading scientific and technological innovation;
Young and middle-aged expert with outstanding contributions to national health and family planning;
The outstanding talent of first batch in TCM clinical practice by the National Administration of TCM;
Leader of key disciplines and key specialties of TCM oncology of the National Administration of TCM;
Secretary of the Party branch and honorary chairman of the Cancer Branch of the China Association of Chinese Medicine;
Member of the 10th and 11th National Pharmacopoeia Committee;
Chairman of China TCM Cancer Prevention and Control Alliance;
Member of China Association of Chinese Medicine.
He studied under Professor Duan Fujin, a national TCM master, and Professor Piao Bingkui, a famous TCM doctor in China. He inherited the idea of "strengthening body resistance and cultivating the foundation" in the treatment of tumors. He has been working in clinic for more than 30 years, and has accumulated rich clinical experience.
With preventive treatment idea, he is good at preventing and treating postoperative recurrence and metastasis of tumors, lung cancer, digestive system tumors, cancer-related symptoms and precancerous lesions with the methods of clearing and reducing turbidity, and activating qi and blood.
He founded the theory of "regulating qi and detoxifying" and applied it to the prevention and treatment of tumors in TCM, and developed a series of Shuangshen tumor prevention and treatment preparations. As the principal investigator of the national key research and development plan, from the "Tenth Five-Year Plan" to the "Thirteenth Five-Year Plan" period, he put forward the concept of tumor prevention and control：prevention first, combining prevention and treatment, and focusing on prevention； and established the first cancer prevention clinic in China. He focused his oncology clinical work on the prevention and rehabilitation of precancerous lesions, recurrence and metastasis, and gave full play to the characteristics and advantages of TCM "preventive treatment".
As the project leader, he has successively undertaken 7 national-level projects such as the National Science and Technology Support Program, the Major New Drug Creation Project, and the Project of National Natural Science Foundation of China, and has successively won 2 second-class national science and technology progress awards, and more than 10 provincial and ministerial science and technology awards, obtained 3 patents, and won the honorary title of "National Health System Advanced Worker". At present, he has published a total of 389 academic papers, including 65 SCI articles, and published more than 20 academic works.
Lyu Wenliang
Vice President and medical professor of Guang'anmen Hospital;
Doctor of TCM in Digestion;
Postdoctor in oncology with integrated TCM and Western medicine;
Doctoral supervisor; postdoctoral cooperative supervisor;
Director of the sub-center of the liver disease clinical research base of the Ministry of Science and Technology;
Director and academic leader of "Twelfth Five-Year" key specialist in liver disease of National Administration of TCM;
Leader of Guang'anmen Hospital of the National TCM Medical Team to fight against COVID-19 in Wuhan, China;
Expert who have obtained special government allowances from the State Council;
Young and middle-aged TCM doctor of the first batch of China Academy of Chinese Medical Sciences;
Famous young and middle-aged TCM doctor in the capital;
Vice President and Secretary General of Chinese Association of Integrative Medicine;
Executive Director of Chinese Medical Association;
Member of the Expert Advisory Committee on Drug Safety and Risk Management and the Drug Registration Review Expert Advisory Committee of the State Food and Drug Administration;
The chief scientist of the project "Clinical Research of Yinqi Sanhuang Jiedu Decoction in the Treatment of Chronic Type B Viral Liver Disease" of " TCM Modernization Research of National Key Research and Development Program " of the Ministry of Science and Technology.
Under the Professor Yao Naili and Professor Sun Guizhi, famous TCM masters in the capital, he studied the comprehensive prevention and treatment of chronic stomach disease, chronic liver disease and liver cancer with TCM and Western medicine. He has a unique understanding of the etiology and pathogenesis of chronic hepatitis, liver cirrhosis and liver cancer by summarizing the experience of doctors in the past dynasties in treating chronic liver disease and combining with his own clinical practice.
He used the methods of invigorating qi and strengthening spleen, soothing liver and relieving depression, clearing dampness and heat, detoxifying, promoting circulation of collaterals and removing stasis to treat liver diseases. In accordance with the law of the development of TCM, he created Yinqi Sanhuang Jiedu Decoction, an experience prescription for preventing and treating chronic hepatitis, liver fibrosis, cirrhosis and liver cancer.
The decoction formula was formed under the guidance of the holism concept of TCM and the theories of treatment based on syndrome differentiation and preventive health care, and its scientific research had been supported by the Key Research Program for the TCM Modernization of National Key Research and Development Program.
As the chief scientist of the program and the leader of the sub-center of the liver disease clinical research base of the Ministry of Science and Technology, he also undertakes the research on major special projects of infectious diseases in the national 11th, 12th, and 13th Five-Year Plan.
He first proposed and advocated the Huo Hou theory of TCM . He is good at preventing and treating liver diseases with integrated TCM and Western medicine, and has unique curative effects on chronic atrophic gastritis and infertility.
He was the first to use clinical epidemiological methods to study the syndromes of hepatitis B fibrosis, filling the gap in the field of TCM research. In cooperation with the National Center for Nanomedicine, he carried out researches on the mechanisms of biomechanopharmacology, genomics after TCM intervention for chronic liver diseases, which are in a pioneering and leading position in China.
Vice President Lyu Wenliang treated patients at Dongxihu Fangcang Hospital in Wuhan, China